Role of Dyslipidemia in Patients With Chronic Kidney Disease

Marino, Anna; Tannock, Lisa R.

doi:10.3810/pgm.2013.07.2676

Cited by 7 publications

(9 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These changes could be observed in the early stages of kidney disease [25,26], and serious kidney dysfunction led to the development of severe dyslipidemia [2,3,27]. In our study, we found a higher LDL-C level in the decreased eGFR group compared to the normal eGFR group.…”

Section: Discussionsupporting

confidence: 64%

“…Previous studies have indicated that patients with kidney disease also exhibit significant alterations in lipid metabolism and that the progression of kidney disease may lead to severe dyslipidemia [2][3][4]. Importantly, it is worth noting that disorders in lipid metabolism can also be observed in patients even in the early stage of kidney dysfunction [5,6].…”

Section: Introductionmentioning

confidence: 99%

“…CAD was defined as 50% diameter stenosis in at least one of the three major coronary arteries assessed by selective coronary angiography. The body mass index was calculated as body weight (kg) divided by body height (m 2 …”

Section: Study Populationmentioning

confidence: 99%

See 2 more Smart Citations

Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population

Zhang

Zhao

et al. 2018

Cardiorenal Med

View full text Add to dashboard Cite

Background: Elevated levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) have been reported to be related to dyslipidemia, including patients with kidney dysfunction. However, its association with estimated glomerular filtration rate (eGFR) in individuals with normal serum creatinine (SCr) has not been determined. Methods: A total of 2,089 subjects with normal SCr and without lipid-lowering treatment were consecutively enrolled in this study. Plasma PCSK9 levels were measured by ELISA kit and eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration equation. Subjects were divided into a normal eGFR group (n = 1,205, ≥90 mL/min/1.73 m²) and a decreased eGFR group (n = 884, < 90 mL/min/1.73 m²). Baseline characteristics and laboratory findings were compared between the two groups. Spearman’s correlation and linear regression were performed to determine the association between PCSK9 and eGFR. Results: No significant difference in PCSK9 levels was found between the normal eGFR group and the decreased eGFR group (236.84 ± 67.87 vs. 239.98 ± 68.72 ng/mL, p = 0.303). In Spearman’s correlation and multivariable linear regression analysis, no association of PCSK9 levels with eGFR was detected in the total cohort (r = –0.039, p = 0.079; adjusted β = –0.013, p = 0.630). This result remained the same in the subgroups of normal eGFR (r = –0.038, p = 0.190; adjusted β = –0.031, p = 0.367) and decreased eGFR (r = –0.054, p = 0.109; adjusted β = –0.034, p = 0.319). Conclusion: In this single-center study with moderate sample size, the data showed no relationship of PCSK9 levels with normal or decreased eGFR in untreated patients with normal SCr, suggesting that further studies may be needed to understand the relationship between PCSK9 and lipid disorder in different stage of kidney dysfunction.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population

Zhang

Zhao

et al. 2018

Cardiorenal Med

View full text Add to dashboard Cite

show abstract

“…The presence of dyslipidemia is associated with CKD in patients and likely contributes to the development of both renal disease and CHD [20]. Lipoprotein metabolism is a dynamic system that can be disturbed in CKD owing to alterations in apolipoproteins, lipid transfer proteins, lipolytic enzymes and lipoprotein receptors.…”

Section: Lipid Profile Testsmentioning

confidence: 99%

Dyslipidemia among patients visiting tertiary care hospital

Singh

Jha²

2013

Janaki Med. Coll. J. Med. Sci.

View full text Add to dashboard Cite

Background and objectives: The lipid profile is a group of tests that are often ordered together to determine risk of various diseases and is likely to be abnormal (dyslipidemia) in persons suffering from Coronary Heart diseases, Diabetes, Chronic Kidney Disease and Nephrotic Syndrome. This study attempts to compare a lipid profile in normal individuals and those suffering from above diseases visiting Institute of Medicine, Maharajgunj, Kathmandu, Nepal.Material and Methods: Three hundred blood samples were collected from Inpatient and Outpatient Department. Out of which 94 blood samples of healthy individuals were assed as controls and 206 as test. The lipid profile tests were performed. All the data were analyzed using SPSS of 13 version, and the data were evaluated.Results: Out of 206 test samples and 94 controls, 116 were dyslipidemic respectively. The prevalence of dyslipidemia were highest in subjects with Coronary Heart Disease (64%) followed by Diabetes (50%). Similarly the prevalence in Chronic Kidney Disease and Nephrotic Syndrome were 43.90% and 12.50% respectively.

show abstract

“…Lipid metabolism abnormalities with alterations in lipid profiles are commonly seen in CKD patients; therefore, the prevalence of dyslipidemia in CKD is much higher than that in the general population [55,56]. Markedly reduced high-density lipoprotein quantity and function is the key dyslipidemia leading to persistent chronic inflammation, increased oxidative stress, and subsequent progression of cardiovascular disease in CKD.…”

Section: Vitamin D and Lipid Metabolismmentioning

confidence: 99%

Pleiotropic Effects of Vitamin D in Kidney Disease

Wu¹,

Lu²

2017

A Critical Evaluation of Vitamin D - Clinical Overview

View full text Add to dashboard Cite

Vitamin D is metabolized in the liver and kidneys and then converted to the active form, 1.25-dihydroxyvitamin D [1.25(OH)2D]. Chronic kidney disease patients usually lack both 25-hydroxyvitamin D [25(OH)D] and 1.25(OH)2D due to impaired renal function and 1α-hydroxylase deficiency. Chronic kidney disease patients have a high incidence of cardiovascular and infectious morbidities. Increasing evidence indicates a relationship between vitamin D deficiency and cardiovascular and infectious mortality risks. Vitamin D may have significant biological effects beyond its traditional roles on mineral and bone metabolism. Many extrarenal cells have the capability to produce local active 1.25(OH)2D in an intracrine or paracrine fashion. Vitamin D has a significant association with nonskeletal diseases, such as immunodeficiency, metabolic syndrome, insulin resistance, diabetes, hyperlipidemia, cardiovascular disease, proteinuria, and acute kidney injury. This article aims to review and summarize the pleiotropic effects of vitamin D in patients with kidney disease, particularly the immunological, metabolic, cardiovascular, and renal effects.

show abstract

Role of Dyslipidemia in Patients With Chronic Kidney Disease

Cited by 7 publications

References 79 publications

Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population

Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population

Dyslipidemia among patients visiting tertiary care hospital

Pleiotropic Effects of Vitamin D in Kidney Disease

Contact Info

Product

Resources

About